(MORE UPDATES COMING... INCLUDING CHARTS, NEWS and OPINIONS)
CHART link below!
NEW YORK, NY--(Marketwired - Oct 29, 2013)
"Aradigm's Lipoquin and Pulmaquin inhalable antibiotics are potential best-in-class treatments designed for chronic use and to be effective at treating bacterial infections in patients' lungs, while also minimizing lung irritation that is common in cystic fibrosis and especially bronchiectasis patients," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "The recent partnership with Grifols provides adequate funding to bring the program through Phase III trials in bronchiectasis and may allow Aradigm to pursue additional indications."
Phase III Program in Bronchiectasis Planned to Launch in 2014; Recent Partnership With Grifols Worth Up to $90 Million Plus Tiered Royalties;
ALBANY, New York, February 25, 2014 /PRNewswire/
Pulmonary Drug Delivery Systems Market Expected to Reach USD 28.7 Billion Globally in 2019: Transparency Market Research
According to a new market report published by Transparency Market Research "Pulmonary Drug Delivery Systems Market(Products- Metered Dose Inhalers, Dry Powder Inhalers and Nebulizers; Applications- Asthma, COPD and Cystic Fibrosis) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global pulmonary drug delivery systems market was valued at USD 21.03billion in 2012 and is expected to grow at a CAGR of4.5% from 2013 to 2019, to reach an estimated value of USD 28.70billion in 2019.
HYATTSVILLE, Maryland Tue Apr 1, 2014 7:49pm EDT
U.S. FDA advisers back MannKind's inhaled diabetes drug Afrezza
ARDM has huge potential with AERx iDMS (inhalable insulin) right now.
The drug was in the last lap of clinical trials before halting by Novo Nordisk in past.
DRUG DELIVERY TECHNOLOGIES MARKET FORECAST 2014-2024
Opportunities for Leading Companies Leading companies and potential for market growth Overall world revenue for drug delivery technologies will reach $138.1bn in 2014, our work forecasts. We predict steady growth from 2014 to 2024. Our work shows you what organisations hold greatest potential. See profiles of 18 leading companies, including these: • 3M • Aradigm Corporation • Vectura Group • Applied Pharma Research • Catalent Pharma Solutions • Emisphere Technologies • Ethypharm • Glycologic • Alkermes • Antares Pharma • Bioject Medical Technologies • Pacira Pharmaceuticals • Nanopass Technologies • Noven Pharmaceuticals • CIMA Labs • Columbia Laboratories • Generex Biotechnology Corporation • pSivida
Sept 22, 2017
Aradigm to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26
Sept 27, 2017
Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status
Oct 10, 2017
Aradigm Regains Compliance with NASDAQ Listing Requirements
SEC Company Filings - Aradigm Corporation